肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2009年
4期
259-260
,共2页
子宫颈肿瘤%化疗疗法,肿瘤,局部灌注
子宮頸腫瘤%化療療法,腫瘤,跼部灌註
자궁경종류%화료요법,종류,국부관주
Uterine cervical neoplasms%Chemotherapy,cancer,regional peffusion
目的 探讨超选择动脉内灌注化疗加栓寒术前治疗晚期子宫颈癌的临床疗效.方法 2004年1月至2008年3月间住院未经治疗的ⅡA~Ⅳ期子宫颈癌患者共26例,术前在数字减影血管造影术监视下,采用Seldinger技术行双侧髂内动脉插管灌注化疗药,卡铂80 mg,长春新碱2 mg,丝裂霉素16 mg,明胶海绵颗粒栓塞肿瘤供血明显的分支.妇科检查结合超声和CT测量化疗前后肿瘤大小,计算肿瘤消退百分比.1个月后行根治性子宫切除术.结果 栓塞化疗总有效率为92.3%.结论 术前化疗可缩小肿瘤病灶,减少淋巴结转移和亚临床播散,增加了根治性子宫切除的机会,有望提高晚期子宫颈癌患者的生活质量和生存率.
目的 探討超選擇動脈內灌註化療加栓寒術前治療晚期子宮頸癌的臨床療效.方法 2004年1月至2008年3月間住院未經治療的ⅡA~Ⅳ期子宮頸癌患者共26例,術前在數字減影血管造影術鑑視下,採用Seldinger技術行雙側髂內動脈插管灌註化療藥,卡鉑80 mg,長春新堿2 mg,絲裂黴素16 mg,明膠海綿顆粒栓塞腫瘤供血明顯的分支.婦科檢查結閤超聲和CT測量化療前後腫瘤大小,計算腫瘤消退百分比.1箇月後行根治性子宮切除術.結果 栓塞化療總有效率為92.3%.結論 術前化療可縮小腫瘤病竈,減少淋巴結轉移和亞臨床播散,增加瞭根治性子宮切除的機會,有望提高晚期子宮頸癌患者的生活質量和生存率.
목적 탐토초선택동맥내관주화료가전한술전치료만기자궁경암적림상료효.방법 2004년1월지2008년3월간주원미경치료적ⅡA~Ⅳ기자궁경암환자공26례,술전재수자감영혈관조영술감시하,채용Seldinger기술행쌍측가내동맥삽관관주화료약,잡박80 mg,장춘신감2 mg,사렬매소16 mg,명효해면과립전새종류공혈명현적분지.부과검사결합초성화CT측양화료전후종류대소,계산종류소퇴백분비.1개월후행근치성자궁절제술.결과 전새화료총유효솔위92.3%.결론 술전화료가축소종류병조,감소림파결전이화아림상파산,증가료근치성자궁절제적궤회,유망제고만기자궁경암환자적생활질량화생존솔.
Objective To investigate the clinical effect of superselective arterial infusion chemotherapy(SACT) and embolization in advanced cervical carcinoma patients before surgery. Methods 26 previously untreated patients with stage ⅡA-Ⅳ cervical carcinoma admitted from January 2004 to March 2008 were enrolled into the study, patients underwent SACT of the internal iliac artery(dose of the drug: CBP 80 rag, VCR 2 rag, MMC 16 mg) by Seldinger technique in the surveillance of DSA, the obvious branches of the tumor blood supply were embolized by gelfoam particles. Size of tumor before and after chemotherapy was measured by gynecological examination combined with B ultrasonic examination and CT, then calculated the percentage of tumor regression. Radical hysterectomy was administered one month after chemotherapy. Results 24 patients were evaluated as PR, the reaction rate of chemotherapy was 92.3 %. Conclusion SACT before surgery can effectively reduce tumor volume, decrease lymphatic metastasis and subclinical dissemination and enhance the opportunity of radical hysterectomy, and to improve the quality of life and OS of the advanced cervical carcinoma patients.